Unusual Toxicity Induced by Radiotherapy

Institut de Cancérologie de Lorraine45 enrolled

Overview

In order to evaluate the physiopathological knowledge of the different pathological manifestations associated with individual radiosensitivity, it seems essential to carry out this pilot study. It has agglomerated homogeneous tissue samples to identify new biomarkers for patient diagnosis and follow-up, and may predict the therapeutic response. These knowledge will help to treatment customization.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Cancer

Interventions

skin biopsyOTHER

skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or "punch", 12 G).

tumor biopsyOTHER

an additional tumor sample will be taken during programmed diagnostic procedure.

blood sampleOTHER

blood sample will be taken for biological collection

Eligibility

Sex: ALLMin age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Child or teenager aged 2 to \<18 * Man, Woman\> 18 years old * Patient with one of these situations: * Unusual toxicity in progress or after radiotherapy * Indication of radiotherapy and suspicion of abnormal pathways of response to ionizing radiation - constitutional (genetic disease) or acquired (systemic disease) - which may generate unusual radioinduced toxicity * Patient information and informed consent signed by the patient. For children and teenager : information to parents and obtaining informed consent * Affiliation to a social security scheme. Exclusion Criteria: * Contraindication for skin and / or tumoral biopsy * Contraindication for blood sample of 2.5 ml * Persons deprived of liberty or under supervision

Locations (1)

Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France

Outcomes

Primary Outcomes

skin fibroblast radiosensitivity

The number of residual double strand break at 24 hours (number of 53BP1 foci) after a dose of 2 Gy will be quantified with indirect immunofluorescence

Time frame: 2 to 3 months after skin biopsy

Secondary Outcomes

tumor cells radiosensitivity

The number of residual double strand break at 24 hours (number of 53BP1 foci) after a dose of 2 Gy will be quantified with indirect immunofluorescence

Time frame: 2 to 3 months after tumor biopsy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.